Pro-dopaminergic pharmacological interventions for anhedonia in depression: protocol for a living systematic review of human and non-human studies.

Autor:	Ostinelli EG; Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre, Oxford, UK.; Department of Psychiatry, University of Oxford, Oxford, England, UK.; Oxford Health NHS Foundation Trust, Oxford, England, UK., Chiocchia V; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland., Macleod M; Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK., Browning M; Department of Psychiatry, University of Oxford, Oxford, England, UK.; Oxford Health NHS Foundation Trust, Oxford, England, UK., Harmer C; Department of Psychiatry, University of Oxford, Oxford, England, UK., Siafis S; Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich, Germany., Stansfield C; EPPI Centre, Social Research Institute, University College London, London, England, UK., Friedrich C; Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre, Oxford, UK.; Department of Psychiatry, University of Oxford, Oxford, England, UK., Wright S; Department of Psychiatry, Stellenbosch University, Stellenbosch, Western Cape, South Africa., Chikaura T; MQ Mental Health Research, London, UK., Milligan L; MQ Mental Health Research, London, UK., Thomas J; EPPI Centre, Social Research Institute, University College London, London, England, UK., Moreno C; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, ISCIII, School of Medicine, Universidad Complutense de Madrid, Madrid, Community of Madrid, Spain., Furukawa TA; Department of Health Promotion and Human Behavior / School of Public Health, Kyoto University, Kyoto, Kyoto Prefecture, Japan., Seedat S; Department of Psychiatry, Stellenbosch University, Stellenbosch, Western Cape, South Africa., Potts J; Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre, Oxford, UK.; Department of Psychiatry, University of Oxford, Oxford, England, UK., Salanti G; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland., Cipriani A; Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre, Oxford, UK.; Department of Psychiatry, University of Oxford, Oxford, England, UK.; Oxford Health NHS Foundation Trust, Oxford, England, UK.
Jazyk:	angličtina
Zdroj:	Wellcome open research [Wellcome Open Res] 2023 Oct 05; Vol. 8, pp. 425. Date of Electronic Publication: 2023 Oct 05 (Print Publication: 2023).
DOI:	10.12688/wellcomeopenres.19870.1
Abstrakt:	Background: Anhedonia is a key symptom of depression, and it has been suggested as a potential target for future individualised treatments. However, much is unknown about how interventions enhancing dopaminergic pathways may affect anhedonia symptoms in the context of depression. Methods: We will perform independent searches in multiple electronic databases to identify clinical and animal experimental studies on pro-dopaminergic interventions in individuals with depression or animal models for depression. The primary outcomes will be overall anhedonia symptoms and their behavioural proxies in animals. Secondary outcomes will include side effects and neurobiological measures. At least two independent reviewers will conduct the study selection, data extraction, and risk of bias assessments using pre-defined tools according to each record's study design. We will develop ontologies to facilitate study identification and data extraction. We will synthesise data from clinical and animal studies separately. If appropriate, we will use random-effects meta-analyses, or synthesis without meta-analyses. We will investigate study characteristics as potential sources of heterogeneity. We will evaluate the confidence in the evidence for each outcome and source of evidence, considering the summary of the association, potential concerns regarding internal and external validity, and reporting biases. When multiple sources of evidence are available for an outcome, we will draw an overall conclusion in a triangulation meeting involving a multidisciplinary team of experts. We plan updates of the review every 6 months, and any future modifications to the protocol will be documented. We will co-produce this review with multiple stakeholders. PROSPERO registration: CRD42023451821. Competing Interests: Competing interests: Edoardo G. Ostinelli received research and consultancy fees from Angelini Pharma. Carmen Moreno received honoraria as a consultant and/or advisor and/or for lectures from Angelini, Compass, Esteve, Exeltis Janssen, Lundbeck, Neuraxpharm, Nuvelution, Otsuka, Pfizer, Servier and Sunovion outside the submitted work. Toshi A Furukawa received personal fees from Boehringer- Ingelheim, DT Axis, Kyoto University Original, Shionogi, and SONY, and a grant from Shionogi outside the submitted work; in addition, TAF has patents 2020-548587 and 2022-082495 pending, and intellectual properties for Kokoro-app licensed to Mitsubishi-Tanabe. Andrea Cipriani received research, educational and consultancy fees from the Italian Network for Paediatric Trials, CARIPLO Foundation, Lundbeck, and Angelini Pharma. (Copyright: © 2023 Ostinelli EG et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu